PHIO vs. SXTP, BCEL, ARAV, RNAZ, NBY, ONCO, AGRX, NOVN, ARDS, and SNOA
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include 60 Degrees Pharmaceuticals (SXTP), Atreca (BCEL), Aravive (ARAV), TransCode Therapeutics (RNAZ), NovaBay Pharmaceuticals (NBY), Onconetix (ONCO), Agile Therapeutics (AGRX), Novan (NOVN), Aridis Pharmaceuticals (ARDS), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "pharmaceutical preparations" industry.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.
60 Degrees Pharmaceuticals currently has a consensus target price of $2.40, suggesting a potential upside of 899.58%. Phio Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 480.47%. Given Phio Pharmaceuticals' higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Phio Pharmaceuticals.
8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.8% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Phio Pharmaceuticals' return on equity of 0.00% beat 60 Degrees Pharmaceuticals' return on equity.
In the previous week, Phio Pharmaceuticals had 3 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 1 mentions for 60 Degrees Pharmaceuticals. Phio Pharmaceuticals' average media sentiment score of 0.55 beat 60 Degrees Pharmaceuticals' score of -0.31 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.
60 Degrees Pharmaceuticals has higher revenue and earnings than Phio Pharmaceuticals.
Phio Pharmaceuticals received 34 more outperform votes than 60 Degrees Pharmaceuticals when rated by MarketBeat users. Likewise, 62.50% of users gave Phio Pharmaceuticals an outperform vote while only 33.33% of users gave 60 Degrees Pharmaceuticals an outperform vote.
Summary
60 Degrees Pharmaceuticals and Phio Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
